Revolutionizing Lung Disease Predictions with AI: Brainomix's New Advances

Introduction to Brainomix and Its AI-Powered Solutions

Brainomix, an innovative company based in Oxford, UK, and Chicago, USA, specializes in creating AI-powered software solutions aimed at precision medicine. Their recent focuses have been on improving treatment decisions for conditions such as stroke and lung fibrosis. The company originated from the University of Oxford and has expanded significantly, operating in over 30 countries worldwide.

Brainomix is renowned for developing award-winning imaging biomarkers and software solutions. Their flagship product, the Brainomix 360 stroke platform, has been adopted by numerous hospitals globally, significantly enhancing stroke treatment rates and patient outcomes.

Breakthrough Studies Presented at the American Thoracic Society Conference

This week, Brainomix made significant strides by presenting a series of new studies at the American Thoracic Society (ATS) Conference in San Diego. These studies shed light on the predictive power of their AI-based imaging biomarkers in patients with lung fibrosis, both idiopathic pulmonary fibrosis (IPF) and non-IPF cases.

The research demonstrated a consistent focus on scientific excellence and academic collaborations, involving esteemed institutions and life science partners worldwide.

Predictive Value in Non-IPF Fibrotic ILD

One standout study, conducted in collaboration with Heidelberg University, analyzed a decade's worth of data from 347 non-IPF patients. This research utilized Brainomix's weighted reticulovascular score (WRVS) as an imaging biomarker. The findings showed that WRVS is a strong predictor of mortality and a significant independent risk factor for a 10% decline in Forced Vital Capacity (FVC). This emphasizes the potential of WRVS in foretelling disease progression in fibrotic lung diseases.

Prof Dr. Michael Kreuter, Director for the Lung Center Mainz, highlighted the study's importance, noting that WRVS could be a valuable tool for predicting disease progression in this patient cohort.

Innovations in Idiopathic Pulmonary Fibrosis (IPF) Studies

Brainomix collaborated with Avalyn Pharma to analyze their Phase 1b clinical trial of inhaled pirfenidone (the ATLAS study) in IPF patients. The study's post-hoc analysis revealed that WRVS could help predict lung disease progression in patients receiving low-dose pirfenidone. These insights could lead to better optimization of AI imaging tools for future clinical trials.

Dr Peter George, Senior Medical Director at Brainomix, emphasized that enhancing AI imaging tools could help match treatment arms more precisely and explore new trial endpoints.

Predictive Biomarkers in AstraZeneca's IPF Clinical Trials

Another significant collaboration with AstraZeneca involved the Phase 2 tralokinumab clinical trial for IPF. This research highlighted that WRVS could accurately predict patients at risk of a 52-week decline in FVC at baseline. These results suggest that this biomarker could play a crucial role in designing sophisticated future clinical trials.

Ross Stewart, Senior Business Development Manager at Brainomix, pointed out the potential for WRVS to inform more effective trial designs.

Concluding Remarks

These studies underscore the potential of AI-based imaging biomarkers from Brainomix in advancing the prediction of lung disease progression. With continued collaboration with leading research institutions and life science partners, Brainomix is well-placed to pioneer innovative solutions that could significantly impact patient care in lung fibrosis.